ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CABA vs LCTX // RETURN ON INVESTED CAPITAL (ROIC)

Cabaletta Bio Inc. (NASDAQ) VS. Lineage Cell Therapeutics Inc. (NYSE) • 15-METRIC TALLY: CABA 1 — LCTX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CABA VS. LCTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CABA LCTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -7.46% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 53.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 LCTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.1 50.8 -13.67 LCTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $268.7M $260.5M $8.2M CABA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CABA REV LCTX REV CABA GROSS % LCTX GROSS % CABA FCF LCTX FCF
FY 2025 $0 $14.6M — — -$132.3M -$19.4M
FY 2024 $0 $9.5M — 96.5% -$90.4M -$23.7M
FY 2023 $0 $8.9M — — -$53.5M -$28.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CABA // BETA —
LCTX // BETA —